Evidence map›Paper›PMID 24643915›Full record

ArticleCNS drugs2014

Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs.

Ellen Lu, Feng Zhu, Yinshan Zhao, Mia van der Kop, Anne Synnes, Leanne Dahlgren, A Dessa Sadovnick, Anthony Traboulsee, Helen Tremlett

Abstract read
PubMed Publisher
In one paragraph

Article in CNS drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Observational
  2. Review
  3. Review
  4. Review
  5. Immunosuppressive drugs and fertility.Orphanet journal of rare diseases · 2015
    Review
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Ellen LuBrain Research Centre and Department of Medicine (Division of Neurology), Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Feng Zhu
Yinshan Zhao
Mia van der Kop
Anne Synnes
Leanne Dahlgren
A Dessa Sadovnick
Anthony Traboulsee
Helen Tremlett
Vancouver Coastal Health Research Institute · CAUniversity of British Columbia · CAUniversity of British Columbia Hospital · CABC Centre for Disease Control · CAB.C. Women's Hospital & Health Centre · CA

Funding

Canadian Institutes of Health Research MOP-106607
6 · The paper itself

Abstract

objectiveThe aim of this study was to determine the incidence of births fathered by men with multiple sclerosis (MS) exposed to a disease-modifying drug (DMD) around the time of conception, and investigate the association between DMD exposure and birth outcomes in newborns of exposed and unexposed MS fathers.

methodsPopulation-based databases in British Columbia (BC), Canada, (the BCMS database, Vital Statistics Birth Registry, Population Data BC Consolidation File/Census GeoData, BC PharmaNet and the BC Perinatal Database Registry) were linked in this retrospective cohort study (1996 to 2010). Multivariate models were used to examine the association between interferon-beta (IFNβ) or glatiramer acetate (GA) exposure (within 64 days prior to or at conception; i.e., the duration of spermatogenesis) with birth weight and gestational age of newborns.

resultsOf 195 births fathered by men with relapsing-onset MS, 80 births (41%) were to fathers treated with a DMD before their child was born, with 53/195 (27%) exposed within 64 days prior to or at the time of conception. Of the 53 exposed births, 37 were to IFNβ and 16 to GA. Mean birth weight of IFNβ-exposed and GA-exposed newborns was similar to that of unexposed newborns (adjusted difference: -107 g for both, p>0.3). IFNβ-exposed and GA-exposed newborns also had comparable mean gestational ages relative to unexposed newborns (adjusted difference: -0.5 and -0.3 weeks, respectively, p>0.2).

conclusionsAbout one in three would-be fathers with MS were exposed to IFNβ or GA around the time of conception; there was no compelling evidence to suggest that exposure was associated with either lower birth weight or gestational age.

Indexed as

Birth WeightGestational AgePaternal ExposureAdultBritish ColumbiaDatabases, FactualFathersFemaleGlatiramer AcetateHumansImmunologic FactorsIncidenceInfant, NewbornInterferon-betaMaleMiddle AgedGlatiramer AcetateImmunologic FactorsInterferon-betaPeptides

Identifiers

PMID24643915
OpenAlexW1975713412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.